Literature DB >> 16085400

Population pharmacokinetic modeling for enterohepatic recirculation in Rhesus monkey.

Magang Shou1, Wei Lu, Prasad H Kari, Cathie Xiang, Yuexia Liang, Ping Lu, Dan Cui, W Bart Emary, Kimberly B Michel, Jennifer K Adelsberger, Janice E Brunner, A David Rodrigues.   

Abstract

Enterohepatic recirculation (EHR) occurs via biliary excretion and intestinal reabsorption of a drug. Drug recycling through EHR can lead to a change in pharmacokinetic (PK) properties, such as reduced clearance (CL), extended half-life (T(1/2)) and increased plasma exposure (AUC). As a result, EHR may prolong the pharmacological effect of drugs. In the present study, the compound (Cpd A) was found to exhibit EHR in Rhesus monkeys associated with a reduction in CL (from 3.8 to 0.33 Lh(-1), IV; from 2.3 to 0.4 Lh(-1), PO), and an increase in T(1/2) (from 0.9 to 18 h, IV) and in AUC (from 1.5 to 17.4 microg h/mL, IV; from 2.8 to 16.3 microg h/mL, PO), by comparing the PK in the monkeys via the interruption of EHR (bile-duct cannulation) with that in the intact monkeys. A population four-compartment model was constructed based on recirculation loops incorporating all possible inputs (bile secretion, a lag-time model for gall bladder emptying, routes and amounts of a single dose administration) to fully evaluate the EHR of Cpd A. The plasma concentrations versus time profiles predicted from the model had a good fit to the values observed in the subjects and were further simulated with 90% confidence interval to demonstrate its utility. Thus, the model could be applied as a useful tool to evaluate the drugs or compounds that undergo EHR in different species.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16085400     DOI: 10.1016/j.ejps.2005.05.010

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  7 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

2.  Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjects.

Authors:  Alexander K Berg; Sumithra J Mandrekar; Katie L Allen Ziegler; Elsa C Carlson; Eva Szabo; Mathew M Ames; Daniel Boring; Paul J Limburg; Joel M Reid
Journal:  J Clin Pharmacol       Date:  2013-02-22       Impact factor: 3.126

3.  Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.

Authors:  Tae Hwan Kim; Soyoung Shin; Cornelia B Landersdorfer; Yong Ha Chi; Soo Heui Paik; Jayhyuk Myung; Rajbharan Yadav; Stefan Horkovics-Kovats; Jürgen B Bulitta; Beom Soo Shin
Journal:  AAPS J       Date:  2015-05-20       Impact factor: 4.009

4.  Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks.

Authors:  Olanrewaju Okusanya; Alan Forrest; Robin DiFrancesco; Sanela Bilic; Susan Rosenkranz; Michael F Para; Elizabeth Adams; Kevin E Yarasheski; Richard C Reichman; Gene D Morse
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

5.  Oral bioavailability and brain penetration of (-)-stepholidine, a tetrahydroprotoberberine agonist at dopamine D(1) and antagonist at D(2) receptors, in rats.

Authors:  Yan Sun; Jieyu Dai; Zheyi Hu; Feifei Du; Wei Niu; Fengqing Wang; Fei Liu; Guozhang Jin; Chuan Li
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

6.  Pharmacogenetic pathway analysis of irinotecan.

Authors:  G L Rosner; J C Panetta; F Innocenti; M J Ratain
Journal:  Clin Pharmacol Ther       Date:  2008-04-16       Impact factor: 6.875

7.  A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma.

Authors:  Simone M Goldinger; Jeannine Rinderknecht; Reinhard Dummer; Felix Pierre Kuhn; Kuo-Hsiung Yang; Lucy Lee; Ruben C Ayala; Jagdish Racha; Wanping Geng; David Moore; Mei Liu; Andrew K Joe; Selby Patricia Gil Bazan; Joseph F Grippo
Journal:  Pharmacol Res Perspect       Date:  2015-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.